Enfermedad ósea de Paget, osteomalacia y sarcopenia

  1. Pino Montes, Javier del
  2. Corral Gudino, Luis
  3. Sánchez, M. D.
  4. Calero Paniagua, Ismael
  5. Carranco Medina, Tatiana Elizabeth
  6. Quesada Moreno, Alba
Zeitschrift:
Medicine: Programa de Formación Médica Continuada Acreditado

ISSN: 0304-5412

Datum der Publikation: 2014

Titel der Ausgabe: Enfermedades óseas: Enfermedades óseas

Serie: 11

Nummer: 60

Seiten: 3555-3566

Art: Artikel

DOI: 10.1016/S0304-5412(14)70814-5 DIALNET GOOGLE SCHOLAR

Andere Publikationen in: Medicine: Programa de Formación Médica Continuada Acreditado

Zusammenfassung

Paget �s disease of bone is a focal disorder with increased osteoclast activity and accelerated bone remodeling. The resulting bone is abnormal, highly vascularized, disorganized and diminished strength. It may be asymptomatic; its main manifestations are deformity, fracture and bone pain. You can add secondary arthropathies to deformity and compression neuropathies. Diagnosis is based on clinical, radiology and elevated alkaline phosphatase. Bisphosphonates normalize bone metabolic activity. Osteomalacia is a disturbance of bone mineralization in the mature adult. The most common causes are vitamin D deficiency and congenital or acquired disorders of metabolism. The clinical symptoms include bone pain, muscle weakness and, rarely, tetany. Treatment involves correcting the vitamin deficiency. It is known as sarcopenia progressive reduction in muscle mass and strength that is often observed in the elderly. It is associated with frailty, limited mobility, increased risk of falls and fractures, and increased mortality. Treatment is primarily preventive physical exercise and proper nutrition.

Bibliographische Referenzen

  • Albagha OME, Visconti MR, Alonso N, Langston AL, Cundy T, Dargie T. Genome wide association study identifies variants at the CSF1, OPTN and TNFRSF11A loci as genetic risk factors for Paget’s disease of bone. Nat Genet. 2010;42:520-4.
  • Altman RD. Muskuloskeletal manifestations of Paget’s disease of bone. Arthritis Rheum. 1980;23:1121-7.
  • Bhan A, Rao AD, Rao DS. Osteomalacia as a result of vitamin D deficiency. Endocrinol Metab Clin North Am. 2010;39:321-31.
  • Bolland MJ, Cundy T. Paget’s disease of bone: clinical review and update. J Clin Pathol. 2013;66:924-27.
  • Corral-Gudino L, Borao-Cengotita-Bengoa M, del Pino-Montes J, Ralston, S. Epidemiology of Paget’s disease of Bone: A systematic review and meta-analysis of secular changes. Bone. 2013;55:347-52.
  • Cortis K, Micallef K, Mizzi A. Imaging Paget’s disease of bone from head to toe. Clin Radiol. 2011;66:662-72.
  • Cruz-Jentoft AJ, Baeyens JP, Bauer JM, Boirie Y, Cederholm T, Landi F. Sarcopenia: European consensus on definition and diagnosis: Report of the European Working Group on Sarcopenia in Older People. Age Ageing. 2010;39:412-23.
  • Cundy T, Davidson J, Rutland MD, Stewart C, DePaoli AM. Recombinant osteoprotegerin for juvenile Paget’s disease. N Engl J Med. 2005;353:918-23.
  • Del Pino-Montes J. La enfermedad de Paget: la historia interminable. Reumatol Clin. 2007;3Supl1:13-5.
  • Del Pino-Montes J, García de Yébenes MJ, Torrijos Eslava A, Morales Piga A, Carbonell Abelló J, Farrerons Minguela J. Características de la enfermedad ósea de Paget en España. Datos del Registro Nacional de Paget. Reumatol Clin. 2009;5:109-14.
  • Devogelaer JP, Bergmann P, Body JJ, Boutsen Y, Goemaere S, Kaufman JM. Management of patients with Paget’s disease: a consensus document of the Belgian Bone Club. Osteoporos Int. 2008;19:1109-17.
  • Edwards JR, Mundy GR. Advances in osteoclast biology: old findings and new insights from mouse models. Nat Rev Rheumatol. 2011;7:235-43.
  • Fukumoto S, Shimizu Y. Fibroblast growth factor 23 as a phosphotropic hormone and beyond. J Bone Miner Metab. 2011;29:507-14.
  • Gifre L, Peris P, Monegal A, Martínez de Osaba MJ, Alvarez L, Guañabens N. Osteomalacia revisited : a report on 28 cases. Clin Rheumatol. 2011;30:639-45.
  • Lever JH. Paget’s disease of bone in Lancashire and arsenic pesticide in cotton mill wastewater: a speculative hypothesis. Bone. 2002;31:434-6.
  • Libicher M, Kasperk C, Daniels-Wredenhagen M, Heye T, Kauczor HU, Nawroth P. Dynamic contrastenhanced MRI for monitoring bisphosphonate therapy in Paget’s disease of bone. Skeletal Radiol. 2013;42:225-30.
  • Mirón Canelo JA, del Pino Montes J, Vicente Arroyo M, Sáenz González MC, and the Paget’s disease of bone study group of Salamanca. Epidemiological study of Paget’s disease of bone in a zone of the Province of Salamanca (Spain). Eur J Epidemiol. 1997;13:801-5.
  • Parvizi J, Klein GR, Sim FH. Surgical management of Paget disease of bone. J Bone Miner Res. 2006;21:75-82.
  • Peris P. Diagnóstico y tratamiento de la osteomalacia por el reumatólogo. Reumatol Clin. 2011;7Suppl2:S22-7.
  • Ralston SH, Langston AL, Reid IR. Pathogenesis and management of Paget’s disease of bone. Lancet. 2008;372:155-63.
  • Ralston SH, Layfield R. Pathogenesis of Paget disease of bone. Calcif Tissue Int. 2012;91:97-113.
  • Reginato AJ, Coquia JA. Musculoskeletal manifestations of osteomalacia and rickets. Best Pract Res Clin Rheumatol. 2003;17:1063-80.
  • Reid IR, Davidson JS, Wattie D, Wu F, Lucas J, Gamble GD. Comparative responses of bone turnover markers to bisphosphonatetherapy in Paget’s disease of bone. Bone. 2004;35:224-30.
  • Reid IR, Lyles K, Su G, Brown J, Walsh J, del Pino-Montes J. Zoledronic acid produces sustained remissions in Paget’s disease: data to 6 years. J Bone Miner Res. 2011;26:2261-70.
  • Russell LA. Osteoporosis and osteomalacia. Rheum Dis Clin North Am. 2010;36:665-80.
  • Ryan PJ, Fogelman I. Bone scintigraphy in metabolic bone disease. Semin Nucl Med. 1997;27:291-305.
  • Sakuma K, Yamaguchi A. Novel intriguing strategies attenuating to sarcopenia. J Aging Res. 2012;2012:251217.
  • Seitz S, Priemel M, Zustin J, Beil FT, Semler J, Minne H. Paget’s disease of bone: histologic analysis of 754 patients. J Bone Miner Res. 2009;24:62-9.
  • Selby PL, Davie MWJ, Ralston SH, Stone MD. Guidelines on the management of Paget’s disease of bone. Bone. 2002;31:366-73.
  • Siris ES, Lyles KW, Singer FR, Meunier PJ. Medical management of Paget’s disease of bone: Indications for treatment and review of current therapies. J Bone Miner Res. 2006;21:94-8.
  • Smith SE, Murphey MD, Motamedi K, Mulligan ME, Resnik CS, Gannon FH. Radiographic spectrum of Paget’s disease of bone and its complications with pathologic correlation. Radiographics. 2002;22:1191-216.
  • Sun Q, Sammut B, Wang FM, Kurihara N, Windle JJ, Roodman GD. TBK1 mediates critical effects of measles virus nucleocapsid protein (MVNP) on pagetic osteoclast formation. J Bone Miner Res. 2014;29:90-102.
  • Takata S, Yasui N, Nakatsuka K, Ralston SH. Evolution of understanding of genetics of Paget’s disease of bone and related diseases. J Bone Miner Metab. 2004;22:519-23.
  • Van Staa TP, Selby P, Leufkens HG, Lyles K, Sprafka JM, Cooper C. Incidence and natural history of Paget’s disease of bone in England and Wales. J Bone Miner Res. 2002;17:465-71.
  • Vasireddy S, Talwalkar A, Miller H, Mehan R, Swinson DR. Patterns of pain in Paget’s disease of bone and their outcomes on treatment with pamidronate. Clin Rheumatol. 2003;22:376-80.
  • Visconti MR, Langston AL, Alonso N, Goodman K, Selby PL, Fraser WD. Mutations of SQSTM1 are associated with severity and clinical outcome in paget disease of bone. J Bone Miner Res. 2010;25:2368-73.
  • Walsh JP. Paget’s disease of bone. Med J Aust. 2004;181:262-5.
  • Walston JD. Sarcopenia in older adults. Curr Opin Rheumatol. 2012;24:623-7.
  • Wermers RA, Tiegs RD, Atkinson EJ, Achenbach SJ, Melton LJ. Morbidity and mortality associated with Paget’s disease of bone: A population-based study. J Bone Miner Res. 2008;23:819-25.
  • White TA, Lebrasseur NK. Myostatin and Sarcopenia: Opportunities and Challenges: A Mini-Review. Gerontology. En prensa 2014.
Fuente de los datos: Dialnet